FDA Approves First-Line Treatment for Advanced Ovarian Cancer
American Cancer Society statistics indicate that women diagnosed with advanced ovarian cancer have a 5-year survival rate of less than 50%. In April, the FDA approved the supplemental New Drug Application for Zejula (niraparib), an oral, once-daily poly (ADP-ribose) polymerase inhibitor, as a monotherapy maintenance treatment for women with advanced epithelial ovarian cancer. Read more.

Chemotherapy Linked to Early Cognitive Loss in Breast Cancer Patients?
According to results of the TAILORx trial published recently in the Journal of Clinical Oncology, the addition of chemotherapy to endocrine therapy in the treatment of early stage hormone receptor-positive, HER2-negative breast cancer was correlated with a considerable rise in the level of perceived cognitive impairment. Read more. 

Study: Talazoparib Did Not Increase Overall Breast Cancer Survival 
The final overall survival (OS) results of the phase III EMBRACA trial indicated that talazoparib failed to demonstrate an OS benefit when compared with physician’s choice of chemotherapy in patients with HER2-negative advanced breast cancer who have a germline BRCA1/2 mutation. Read more.